Bukwang Pharmaceutical Co., Ltd.
KRX:003000.KS
4820 (KRW) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 125,928.241 | 190,909.365 | 182,491.221 | 169,659.754 | 168,193.616 | 194,223.518 | 150,743.454 | 138,617.594 | 142,132.09 | 141,687.31 | 130,794.937 | 147,525.248 | 101,218.841 | 180,621.167 | 170,810.033 | 161,578.385 | 155,670.536 | 137,523.643 |
| Cost of Revenue
| 75,882.67 | 111,480.555 | 106,733.238 | 98,018.538 | 83,944.834 | 79,217.674 | 70,114.606 | 62,326.535 | 59,287.432 | 60,452.078 | 60,039.218 | 67,930.681 | 44,960.968 | 74,866.564 | 72,654.633 | 65,266.272 | 58,847.288 | 60,223.007 |
| Gross Profit
| 50,045.571 | 79,428.809 | 75,757.984 | 71,641.215 | 84,248.782 | 115,005.845 | 80,628.848 | 76,291.059 | 82,844.658 | 81,235.232 | 70,755.719 | 79,594.567 | 56,257.873 | 105,754.603 | 98,155.4 | 96,312.113 | 96,823.248 | 77,300.636 |
| Gross Profit Ratio
| 0.397 | 0.416 | 0.415 | 0.422 | 0.501 | 0.592 | 0.535 | 0.55 | 0.583 | 0.573 | 0.541 | 0.54 | 0.556 | 0.586 | 0.575 | 0.596 | 0.622 | 0.562 |
| Reseach & Development Expenses
| 38,929.209 | 24,274.42 | 22,464.642 | 18,032.396 | 17,312.225 | 24,639.522 | 25,067.101 | 18,677.493 | 14,878.751 | 10,229.198 | 7,242.475 | 8,896.43 | 6,112.929 | 6,584.149 | 4,519.739 | 4,703.471 | 4,263.681 | 2,876.391 |
| General & Administrative Expenses
| 4,467.054 | 5,050.243 | 4,434.856 | 4,475.176 | 7,187.006 | 6,806.802 | 6,609.874 | 6,540.316 | 6,023.389 | 5,838.739 | 6,476.859 | 8,247.467 | 6,533.612 | 12,480.18 | 10,048.828 | 9,365.718 | 8,816.368 | 7,688.259 |
| Selling & Marketing Expenses
| 17,638.503 | 14,771.894 | 9,059.035 | 10,788.192 | 15,048.254 | 13,327.296 | 9,885.946 | 12,184.31 | 8,798.892 | 9,987.803 | 9,786.677 | 13,493.683 | 13,315.416 | 10,850.333 | 12,584.664 | 14,366.609 | 12,933.784 | 13,135.718 |
| SG&A
| 48,613.122 | 19,822.138 | 13,493.891 | 15,263.368 | 22,235.26 | 20,134.097 | 16,495.82 | 18,724.626 | 14,822.281 | 15,826.543 | 16,263.536 | 21,741.151 | 19,849.028 | 23,330.513 | 22,633.492 | 23,732.327 | 21,750.152 | 20,823.977 |
| Other Expenses
| 1,107.275 | 35,562.887 | 34,177.57 | 34,317.301 | 35,163.87 | 35,105.426 | 280.724 | 8,099.497 | 2,818.949 | -461.325 | -460.214 | 220.448 | 13.562 | -924.172 | -929.24 | -460.002 | 267.577 | -242.751 |
| Operating Expenses
| 87,542.331 | 79,659.444 | 70,136.103 | 67,613.065 | 74,711.355 | 79,879.045 | 72,952.92 | 67,751.95 | 59,556.566 | 52,876.862 | 47,763.188 | 58,154.184 | 47,747.866 | 66,560.964 | 59,079.708 | 57,058.606 | 54,363.557 | 50,802.951 |
| Operating Income
| -37,496.76 | 1,549.466 | 5,621.881 | 583.649 | 9,537.427 | 35,126.8 | 7,675.928 | 8,539.108 | 23,288.093 | 28,358.371 | 22,992.53 | 21,440.383 | 7,350.09 | 39,193.641 | 39,075.69 | 39,253.508 | 42,459.69 | 26,497.688 |
| Operating Income Ratio
| -0.298 | 0.008 | 0.031 | 0.003 | 0.057 | 0.181 | 0.051 | 0.062 | 0.164 | 0.2 | 0.176 | 0.145 | 0.073 | 0.217 | 0.229 | 0.243 | 0.273 | 0.193 |
| Total Other Income Expenses Net
| -1,171.891 | -2,582.338 | -1,834.55 | -8,883.294 | -10,899.237 | 155,928.848 | 7,207.425 | 12,492.419 | 8,551.832 | 1,241.212 | 2,590.951 | 1,794.962 | 155.876 | -1,040.228 | -2,214.665 | 313.044 | 3,232.812 | 1,139.113 |
| Income Before Tax
| -38,668.651 | -1,032.872 | 3,787.331 | -8,299.645 | -1,361.81 | 191,055.647 | 14,883.353 | 21,031.527 | 31,839.925 | 29,599.583 | 25,583.482 | 23,235.345 | 7,505.966 | 38,153.413 | 36,861.025 | 39,566.552 | 45,692.502 | 27,636.801 |
| Income Before Tax Ratio
| -0.307 | -0.005 | 0.021 | -0.049 | -0.008 | 0.984 | 0.099 | 0.152 | 0.224 | 0.209 | 0.196 | 0.158 | 0.074 | 0.211 | 0.216 | 0.245 | 0.294 | 0.201 |
| Income Tax Expense
| -5,162.874 | 3,215.805 | 6,584.128 | 1,805.017 | 6,073.033 | 45,398.216 | 3,792.726 | 5,224.092 | 6,700.519 | 5,983.376 | 6,051.447 | 6,723.431 | 1,099.841 | 10,759.292 | 8,987.909 | 8,952.115 | 12,667.172 | 8,089.965 |
| Net Income
| -31,329.661 | -4,248.677 | -2,796.798 | -10,104.662 | -7,434.843 | 145,670.056 | 11,090.627 | 15,807.435 | 25,139.405 | 23,616.207 | 19,532.034 | 16,511.915 | 6,406.125 | 27,394.121 | 27,873.116 | 30,880.035 | 32,820.365 | 19,546.836 |
| Net Income Ratio
| -0.249 | -0.022 | -0.015 | -0.06 | -0.044 | 0.75 | 0.074 | 0.114 | 0.177 | 0.167 | 0.149 | 0.112 | 0.063 | 0.152 | 0.163 | 0.191 | 0.211 | 0.142 |
| EPS
| -457.67 | -62.07 | -40.85 | -147.23 | -103.65 | 2,613.89 | 161.84 | 222.2 | 354.19 | 336.67 | 275.21 | 233.91 | 93.42 | 376.05 | 380.37 | 423.24 | 466.46 | 282.67 |
| EPS Diluted
| -457.67 | -62.07 | -40.85 | -147.23 | -103.65 | 2,613.89 | 161.84 | 222.2 | 353.69 | 336.67 | 275.21 | 233.91 | 93.42 | 376.05 | 380.37 | 423.24 | 466.46 | 282.67 |
| EBITDA
| -33,204.322 | 6,665.995 | 9,877.84 | 6,741.447 | 16,999.526 | 39,238.496 | 13,649.814 | 26,508.01 | 24,853.937 | 34,035.467 | 33,335.193 | 32,678.562 | 15,546.844 | 46,561.02 | 42,332.276 | 45,632.766 | 49,878.423 | 29,638.357 |
| EBITDA Ratio
| -0.264 | 0.035 | 0.054 | 0.04 | 0.101 | 0.202 | 0.091 | 0.191 | 0.175 | 0.24 | 0.255 | 0.222 | 0.154 | 0.258 | 0.248 | 0.282 | 0.32 | 0.216 |